Adrebloc100 mg/10 ml
IV Injection
Esmolol Hydrochloride
ZAS Corporation
Product Code : 351
10% Off
Best PriceTk
/
1
Medicine overview
Indications of Adrebloc 100 mg/10 ml
Adrebloc 100 mg/10 ml is a beta adrenergic blocker indicated for the short-termtreatment of:
Control of ventricular rate in supraventricular tachycardia including atrial fibrillation and atrial flutter and control of heart rate in noncompensatory sinus tachycardia.
Control of perioperative tachycardia and hypertension.
Dosage of Adrebloc 100 mg/10 ml
Administer intravenously. Titrate using ventricular rate or blood pressure at ≥4 minute intervals. Supraventricular tachycardia (SVT) or noncompensatory sinus tachycardia-
Optional loading dose: 500 mcg per kg infused over one minute
Then 50 mcg per kg per minute for the next 4 minutes
Adjust dose as needed to a maximum of 200 mcg per kg per minute
Additional loading doses may be administered
Perioperative tachycardia and hypertension-
Loading dose: 500 mcg per kg over 1 minute for gradual control (1 mg per kg over 30 seconds for immediate control).
Than 50 mcg per kg per minute for gradual control (150 mcg per kg per minute for immediate control) adjusted to a maximum of 200 (tachycardia) or 300 (hypertension) mcg per kg per minute.
Interaction of Adrebloc 100 mg/10 ml
Digitalis glycosides: Risk of bradycardia
Anticholinesterases: Prolongs neuromuscular blockade
Antihypertensive agents: Risk of rebound hypertension
Sympathomimetic drugs: Dose adjustment needed
Vasoconstrictive and positive inotropic effect substances: Avoid concomitant use
Contraindications
Severe sinus bradycardia
Heart block greater than first degree
Sick sinus syndrome
Decompensated heart failure
Cardiogenic shock
Coadministration of IV cardiodepressant calcium-channel antagonists (e.g. verapamil) in close proximity to Esmolol hydrochloride
Pulmonary hypertension
Known hypersensitivity to esmolol
Side Effects of Adrebloc 100 mg/10 ml
Most common adverse reactions (incidence> 10%) are symptomatic hypotension (hyperhidrosis, dizziness) and asymptomatic hypotension.
Precautions & Warnings
Risk of hypotension, bradycardia, and cardiac failure: Reduce or discontinue use
Risk of exacerbating reactive airway disease
Diabetes mellitus: Increases the effect of hypoglycemic agents and masks hypoglycemic tachycardia
Risk of unopposed alpha-agonism and severe hypertension in untreated pheochromocytoma
Risk of myocardial ischemia when abruptly discontinued in patients with coronary artery disease
Storage Conditions
Keep below 25°C temperature, away from light & moisture. Keep out of the reach of children.
Drug Classes
Anti adrenergic agent (Beta blockers)
Mode Of Action
Adrebloc 100 mg/10 ml is a beta-1 selective (cardioselective) adrenergic receptor blocking agent with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilizing activity at therapeutic dosages. Its elimination half-life after intravenous infusion is approximately 9 minutes. Adrebloc 100 mg/10 ml inhibits the beta 1 receptors located chiefly in cardiac muscle, but this preferential effect is not absolute and at higher doses it begins to inhibit beta 2 receptors located chiefly in the bronchial and vascular musculature.
Pregnancy
Pregnancy Category C. Esmolol hydrochloride has been shown to produce increased fetal resorptions with minimal maternal toxicity in rabbits when given in doses approximately 8 times the maximum human maintenance dose (300 mcg/kg/min). There are no adequate and well-controlled studies in pregnant women. Adrebloc 100 mg/10 ml should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Adrebloc 100 mg/10 ml, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Pediatric Uses
Pediatric Use: The safety and effectiveness of Adrebloc 100 mg/10 ml in pediatric patients have not been established.Geriatric Use: Clinical studies of Adrebloc 100 mg/10 ml did not include sufficient numbers of subjects aged 65 and over to determine whether they responded differently from younger subjects. Hepatic Impairment: No special precautions are necessary in patients with hepatic impairment because Adrebloc 100 mg/10 ml is metabolized by red-blood cell esterases.Renal Impairment: No dosage adjustment is required for esmolol in patients with renal impairment receiving a maintenance infusion of esmolol 150 mcg/kg for 4 hours.
Disclaimer
The information provided is accurate to our best practices, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy. The absence of specific information about a drug should not be seen as an endorsement. We are not responsible for any consequences resulting from this information, so consult a healthcare professional for any concerns or questions.